Boostrix is named as an intervention in 3 current clinical trials in our Canada, Japan and South Korea registers. 2 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Canadian Immunization Research Network (1). The most-studied condition is RSV.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy
NCT07097012 · ClinicalTrials.gov ↗ · RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Pregnancy
|
Phase 4 | Recruiting | Canadian Immunization Research Network | Canada |
|
A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults
NCT06997627 · ClinicalTrials.gov ↗ · Tetanus-diphtheria-acellular Pertussis (Tdap)
|
Phase 1/2 | Recruiting | GC Biopharma Corp | South Korea |
|
A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women
NCT07596199 · ClinicalTrials.gov ↗ · Diphtheria-Tetanus-acellular Pertussis Vaccines
|
Phase 3 | Active, closed | GlaxoSmithKline | Japan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Canadian Immunization Research Network | 1 |
| GlaxoSmithKline | 1 |
| GC Biopharma Corp | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Japan | 1 | 0 |
| Clinical trials in South Korea | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our Canada, Japan and South Korea registers name Boostrix as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in Canada and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Canadian Immunization Research Network (1), GlaxoSmithKline (1) and GC Biopharma Corp (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Boostrix works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Boostrix works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Boostrix (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.